SGMT: Sagimet Biosciences Inc. - Summary | Jitta

Sagimet Biosciences Inc.

NASDAQ:SGMT

Price
$6.52
Loss Chance
58.9%
0.59JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (9)
Recent Business Performance (22)
Financial Strength (25)
Return to Shareholders (0)
Competitive Advantage (11)
Jitta Signs
Cash Conversion CycleLess than 30 days
Recent IPOLess than 3 years
Recent Business PerformanceEarning decline 9.59% in the last year
CapExVery High
Key Stats
Jitta Score
Jitta Line
0.59
100.00%
2.22
131.45%
3.06
160.82%
Biotechnology
5.68
37.80%
5.68
37.80%
6.36
42.70%
COMPANY DESCRIPTION
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.